Efficacy and safety of nab-paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment for patients with advanced gastric cancer: A single institutional experience

被引：0
|
作者：
Okunaka, Mashiro
Kotani, Daisuke
Demachi, Ken
Kawazoe, Akihito
Yoshino, Takayuki
Shitara, Kohei
机构：
[1] Natl Canc Ctr Hosp East, Dept Pharm, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[4] Natl Canc Ctr Hosp East, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
322
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A multicenter retrospective study of Paclitaxel vs. Paclitaxel plus Ramucirumab for advanced gastric cancer patients
    Imazeki, Hiroshi
    Sakamoto, Takeshi
    Nakano, Michitaka
    Negoro, Yuji
    Yamaga, Satoru
    Kawakami, Kentaro
    Nishikawa, Kazuo
    Izawa, Naoki
    Boku, Narikazu
    Tsuda, Masahiro
    Esaki, Taito
    Makiyama, Akitaka
    Okuda, Hiroyuki
    Tsuda, Takashi
    Minashi, Keiko
    Hironaka, Shuichi
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
    Wang, Jianzheng
    He, Yunduan
    Zhang, Baiwen
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    Cheng, Xiaojiao
    Li, Qingli
    Tu, Shuiping
    Chen, Xiaobing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Fukahori, Masaru
    Okabe, Yoshinobu
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Ushijima, Tomoyuki
    Miwa, Keisuke
    Shibuki, Taro
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [34] Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer
    Kimura, Michio
    Usami, Eiseki
    Teramachi, Hitomi
    Yoshimura, Tomoaki
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (06) : 403 - 411
  • [35] Nab-paclitaxel as second-line treatment in advanced biliary cancer.
    Prager, Gerald W.
    Kornek, Gabriela
    Scheithauer, Werner
    Steger, Guenther G.
    Zielinski, Christoph
    Unseld, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [36] Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Lu, Ming
    Shen, Lin
    Zhou, Jun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12657 - 12666
  • [37] Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Kato, Ryo
    Ueda, Masami
    Tsuda, Yujiro
    Nakashima, Shinsuke
    Ohta, Katsuya
    Matsuyama, Jin
    Ikenaga, Masakazu
    Tominaga, Shusei
    CANCER REPORTS, 2020, 3 (02)
  • [38] Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial
    Kim, Seung Tae
    Sa, Jason K.
    Oh, Sung Yong
    Kim, Kyung
    Hong, Jung Yong
    Kang, Won Ki
    Kim, Kyoung-Mee
    Lee, Jeeyun
    GENOME MEDICINE, 2021, 13 (01)
  • [39] Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer
    Fukuchi, Minoru
    Mochiki, Erito
    Ishiguro, Toru
    Ogura, Toshiro
    Sobajima, Jun
    Kumagai, Youichi
    Ishibashi, Keiichiro
    Ishida, Hideyuki
    ANTICANCER RESEARCH, 2016, 36 (12) : 6699 - 6703
  • [40] Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial
    Seung Tae Kim
    Jason K. Sa
    Sung Yong Oh
    Kyung Kim
    Jung Yong Hong
    Won Ki Kang
    Kyoung-Mee Kim
    Jeeyun Lee
    Genome Medicine, 13
12345